IPO is one of the clinical sites that will host the ONCOSCREEN clinical trials in Porto, Portugal. It actively participates in observational studies, identification of colorectal cancer biomarkers with the focus on the liquid-based screening technologies, retrospective data collection and analysis, and collection of end-user requirements. Furthermore, IPO participates and contributes to the actual implementation of the clinical trials.
To learn more about the role IPO play in ONCOSCREEN, watch the video below.